Recurrent events among Acute Coronary Syndrome patients: gender-specific analysis from Aegean-Islands study

Matina Kouvari, Demosthenes B Panagiotakos, NG Patsourakos, A Kotidis, S Chantanis, K Kalantzi, M Tsoumani, A Kartalis, N Smyrnioudis, S Fousas, AD Tselepis


Aim: To evaluate the 6-month recurrent major adverse cardiac events (MACE) in acute coronary syndrome (ACS) patients, in relation to region and clopidogrel treatment separately for men and women. Material and Methods: During 2016, n=1,194 consecutive ACS patients hospitalized in various Cardiology Clinics in Aegean islands and Attica region, were enrolled. Clopidogrel treatment was recorded either as original product clopidogrel hydrogen sulphate (Plavix®/Iscover®) (branded) or clopidogrel besylate formulation (generic). Six-month follow-up evaluation was performed and recurrent MACE incidence and hemorrhage event were recorded. Results: The 6-month MACE incidence was 3.9% (4.6% in Aegean islands and 3.5% in Attica area, p>0.05). The respective incidence in men was 4.0% and in women 3.8% (p>0.05). Overall generic and branded clopidogrel use was 87% and 13%, respectively. No significant differences were observed between branded and generic clopidogrel use and 6-month MACE incidence; subgroup analysis with gender as strata, did not reveal any significant outcomes as well. Hemorrhage incidence did not exceed the 1% in the total sample. Conclusions: The low incidence of recurrent MACE in ACS patients along with the low rate of bleeding events, irrespective of type of clopidogrel used, support the clinical and safety equivalence of generic and branded clopidogrel in the cardiac rehabilitation of ACS men and women patients.  


clopidogrel besylate; acute coronary syndrome; cardiovascular disease; generic clopidogrel; gender; secondary prevention

Full Text:



U.S. Department of Health and Human Services (HHS), Office of Disease Prevention and Health Promotion ODPHP Publication No. B0132 November 2010. Available at:

Mariolis A, Foscolou A, Tyrovolas S et al. Successful Aging among Elders Living in the Mani Continental Region vs. Insular Areas of the Mediterranean: the MEDIS Study. Aging Dis 2016, 7:285-294.

Tyrovolas S, Chalkias C, Morena M et al. Health care access and prevalence of the metabolic syndrome among elders living in high-altitude areas of the Mediterranean islands: the MEDIS study. Rev Diabet Stud 2011, 8:468-476.

Manzoli L, Flacco ME, Boccia S et al. Generic versus brand-name drugs used in cardiovascular diseases. Eur J Epidemiol 2016, 31:351-368.

Choudhry NK, Denberg TD, Qaseem A; Clinical Guidelines Committee of American College of Physicians. Improving Adherence to Therapy and Clinical Outcomes While Containing Costs: Opportunities From the Greater Use of Generic Medications: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med 2016, 164:41-49.

Tsoumani ME, Kalantzi KI, Goudevenos IA et al. Clopidogrel generic formulations in the era of new antiplatelets: a systematic review. Curr Vasc Pharmacol 2014, 12:766-777.

Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000, 21:1502-1513

Braunwald E. Heart Disease 2000, 5th edited by W.B. Saunders Company, London, UK.

Elek P, Harsányi A, Zelei T et al. Policy objective of generic medicines from the investment perspective: The case of clopidogrel. Health Policy 2017, 121:558-565. doi: 10.1016/j.healthpol.2017.02.015. Epub Ahead of Print.

Wouters OJ, Kanavos PG, McKEE M. Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending. Milbank Q 2017, 95:554-601.

Dunne SS, Dunne CP. What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugs. BMC Med 2015, 13:173.

Colgan S, Faasse K, Martin LR et al. Perceptions of generic medication in the general population, doctors and pharmacists: a systematic review. BMJ Open 2015, 5:e008915.

Xanthopoulou SS, Katsaliaki K. Policies and perceptions on generic drugs: The case of Greece. Health Serv Manage Res 2018 [Epub ahead of print].

Kaló Z, Holtorf AP, Alfonso-Cristancho R et al. Need for multicriteria evaluation of generic drug policies. Value Health 2015, 18:346-351.

Ntalas IV, Kalantzi KI, Tsoumani ME et al. Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial. Curr Vasc Pharmacol 2015, 13:809-818.

Ntalas IV, Kalantzi KI, Tsoumani ME et al. Salts of Clopidogrel: Investigation to Ensure Clinical Equivalence: A 12-Month Randomized Clinical Trial. J Cardiovasc Pharmacol Ther 2016, 21:516-525.

Caldeira D, Fernandes RM, Costa J et al. Branded versus generic clopidogrel in cardiovascular diseases: a systematic review. J Cardiovasc Pharmacol 2013, 61:277-282.

National Institutes of Health. Consideration of Sex as a Biological Variable in NIH-funded Research [Online] 2015 [cited 2017]. Available at:

Kouvari M, Yannakoulia M, Souliotis K et al. Challenges in Sex- and Gender-Centered Prevention and Management of Cardiovascular Disease: Implications of Genetic, Metabolic, and Environmental Paths. Angiology 2018, 3319718756732. [Epub ahead of print].

Berger JS, Bhatt DL, Cannon CP et al. The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. J Am Coll Cardiol 2009, 54:1935-1945.

Xhyheri B, Bugiardini R. Diagnosis and treatment of heart disease: are women different from men? Prog Cardiovasc Dis 2010, 53:227-236. doi: 10.1016/j.pcad.2010.07.004.

Wilkins E, Wilson L, Wickramasinghe K et al. European Cardiovascular Disease 6 Statistics 2017. European Heart Network, Brussels.




  • There are currently no refbacks.